Abstract
In the Phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), a single priming dose of tremelimumab (anti-CTLA-4) plus durvalumab (anti-PD-L1) in the STRIDE regimen significantly improved overall survival vs sorafenib, and durvalumab monotherapy was noninferior to sorafenib (Abou-Alfa et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2100070). Liver function is frequently impaired in patients with HCC, and it is important to evaluate the efficacy and safety of systemic therapies for these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
